If the market realises that RACE is trading at 25% to 30% of the value of preclinical/Phase 1 Precision Oncology peers in the United States then RAC will eventually re-rate.
It's a complex field to understand though so it is very difficult for market to understand the extreme value to a Big Pharma underlying the clinical plan and RAC's strategy for unlocking it.
We know the drug has strong performance due to the historic approval for AML and the Israel trial last year. Also read up on the preclinical results released in the last 12 months.
Comparative analysis is speculative and not intended as advice.
Do your own research and analysis.
RAC has been in a long period of share price consolidation (6 months).
The average market cap of the peers above is AUD $1.74B.
This equates to a share price about $11.90 (undiluted).
RAC is currently trading at a market cap of AUD $496M.
My post #:56506301 has my peer analysis of cancer biotech partnerships and buyouts.
General Comments / Chat, page-4158
-
- There are more pages in this discussion • 7,062 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
